These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

779 related items for PubMed ID: 31409608

  • 1. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
    Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T.
    Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
    [Abstract] [Full Text] [Related]

  • 2. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.
    Clin Cancer Res; 2011 Dec 15; 17(24):7785-95. PubMed ID: 21933893
    [Abstract] [Full Text] [Related]

  • 3. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.
    Eur J Haematol; 2012 Jun 15; 88(6):510-7. PubMed ID: 22413767
    [Abstract] [Full Text] [Related]

  • 4. Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients.
    Huang Y, Ye S, Cao Y, Li Z, Huang J, Huang H, Cai M, Luo R, Lin T.
    ScientificWorldJournal; 2012 Jun 15; 2012():897178. PubMed ID: 23213304
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC, Chung Y, Jang S, Park CJ, Chi HS, Huh J, Suh C, Shim H.
    Medicine (Baltimore); 2018 Nov 15; 97(45):e13046. PubMed ID: 30407302
    [Abstract] [Full Text] [Related]

  • 6. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y, Li ZM, Shi YX, Xia ZJ, Jiang WQ, Huang HQ.
    Ai Zheng; 2009 Feb 15; 28(2):146-9. PubMed ID: 19550126
    [Abstract] [Full Text] [Related]

  • 7. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 8. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.
    J Clin Oncol; 2015 Jan 20; 33(3):251-7. PubMed ID: 25135992
    [Abstract] [Full Text] [Related]

  • 9. Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma.
    Gang AO, Pedersen MØ, Knudsen H, Lauritzen AF, Pedersen M, Nielsen SL, Brown P, Høgdall E, Klausen TW, Nørgaard P.
    Leuk Lymphoma; 2015 Jul 20; 56(7):2039-46. PubMed ID: 25379621
    [Abstract] [Full Text] [Related]

  • 10. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
    He XH, Li B, Yang S, Lu N, Zhang X, Zou SM, Li YX, Song YW, Zheng S, Dong M, Zhou SY, Yang JL, Liu P, Zhang CG, Qin Y, Feng FY, Shi YK.
    Chin J Cancer; 2012 Jun 20; 31(6):306-14. PubMed ID: 22640627
    [Abstract] [Full Text] [Related]

  • 11. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study Group.
    J Clin Oncol; 2017 Aug 01; 35(22):2515-2526. PubMed ID: 28525305
    [Abstract] [Full Text] [Related]

  • 12. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R, Miyoshi H, Takeuchi M, Miyawaki K, Nakashima K, Yoshida N, Kawamoto K, Yanagida E, Yamada K, Umeno T, Suzuki T, Kato K, Takizawa J, Seto M, Akashi K, Ohshima K.
    Cancer Sci; 2020 Jul 01; 111(7):2608-2619. PubMed ID: 32342603
    [Abstract] [Full Text] [Related]

  • 13. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao HL, Liu Q, Jiang WQ, Huang HQ, Lin TY, Xia ZJ.
    Chin J Cancer; 2016 Sep 13; 35(1):87. PubMed ID: 27624700
    [Abstract] [Full Text] [Related]

  • 14. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
    Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, Ferhanoglu B.
    Blood; 2015 Oct 15; 126(16):1893-901. PubMed ID: 26232170
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
    Balasubramanian S, Wang S, Major C, Hodkinson B, Schaffer M, Sehn LH, Johnson P, Zinzani PL, Carey J, Shreeve SM, Sun S, Gerecitano J, Vermeulen J, Staudt LM, Wilson W.
    Br J Haematol; 2021 Jul 15; 194(1):83-91. PubMed ID: 33942292
    [Abstract] [Full Text] [Related]

  • 18. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H.
    J Clin Oncol; 2014 Dec 10; 32(35):3996-4003. PubMed ID: 25385729
    [Abstract] [Full Text] [Related]

  • 19. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T.
    Cancer Sci; 2009 Oct 10; 100(10):1842-7. PubMed ID: 19656156
    [Abstract] [Full Text] [Related]

  • 20. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
    Xu J, Oki Y, Saksena A, Desai P, Lin P, Tang G, Yin CC, You MJ, Thakral B, Medeiros LJ, Li S.
    Hum Pathol; 2017 Feb 10; 60():160-166. PubMed ID: 27816715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.